What are the options in HER2 postive breast cancer treatments are we moving to t-DXd in first line?
Hassan GHAZAL
oncologist, Dubai
oncologist, Dubai
Ethical issues of screening and breast cancer management
Anas Alexis CHEBIB
Where do we stand in developing radionuclides against molecular markers overexpressed on breast cancer (BC) cells such as EGFR-family members?
Willy Vangu
nuclear medicine, Johannesburg, South Africa
Preoperative assessment with FDG Pet CT scan.
9.00 I 9.15
Eric ZERBIB
What’s your take on new breast cancer treatments?
Georgia DEMETRIOU
oncologist, Johannesburg, SA